Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at [email protected].
Latest Media Coverage
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2020
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
Wall Street Journal
FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
The Times
Siggi Olafsson interview — Trump’s medicine man rides the storm
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Browse the archive
FierceBiotech
ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half
Previously, EvaluatePharma’s researchers estimated that inclisiran sales could reach $1.529 billion by that time, but analysts would prefer to see that number top at…
FierceBiotech
Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer
Analysts at EvaluatePharma have estimated the drug will be bringing in $2.4 billion in annual sales by 2024.
The Pharma Letter
Look back at pharma news in the week to March 13, 2020
Its 2022 forecast stands at an awesome $5.2 billion, EvaluatePharma computes, versus a little over $2 billion that it had in 2016 been thought capable of selling.
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2019
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Handelszeitung
How is the pharmaceutical industry doing in the coronavirus stress test?
Market researcher Evaluate Pharma put the volume of deals for infectious diseases in the field of infectious diseases last year at $280 million last year.
Finanz und Wirtschaft
Pharmaceutical suppliers build in Switzerland
The market for service providers is expected to grow between 6 and 9% in the next few years, while the pharmaceutical market as a whole should grow by 5.9% annually…
Wall Street Journal
Insulin Giant Aims to Unlock Elusive Obesity-Drug Market
After Saxenda was approved in 2014, analysts forecast that its U.S. sales would top $250 million by 2020, according to a compilation of estimates by market-research firm…
FiercePharma
Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts
According to EvaluatePharma, drugs designated as orphan drugs will grow by 12.3% per year and top $242 billion in sales by 2024.
The Pharma Letter
Speedy review for PharmaMar's Zepsyre
By 2024, if approved, EvaluatePharma has said it expects the option to reach peak sales of up to $200 million.
FiercePharma
Sanofi CEO Hudson singles out his digital ambitions in big executive shakeup
Last year, 78% of the company’s sales came from products that are over 10 years old, analysts at Vantage pointed out in a report released last month.